Meyka AI API is live for developers.Start building.
Advertisement
Neuronetics, Inc.

Neuronetics, Inc. Fundamental Analysis

STIMNASDAQ
HealthcareMedical - Diagnostics & Research
$1.29
$0.17(11.64%)
U.S. Market opens in 54h 36m
Advertisement

Neuronetics, Inc. Fundamental Analysis

Neuronetics, Inc. (STIM) shows moderate financial fundamentals with a PE ratio of -2.37, profit margin of -24.48%, and ROE of -1.65%. The company generates $0.2B in annual revenue with strong year-over-year growth of 99.17%.

Key Strengths

Cash Position14.72%
PEG Ratio-0.02
Current Ratio1.67

Areas of Concern

ROE-1.65%
Operating Margin-19.40%
We analyze STIM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -153.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-153.2/100

We analyze STIM's fundamental strength across five key dimensions:

Efficiency Score

Weak

STIM struggles to generate sufficient returns from assets.

ROA > 10%
-29.59%

Valuation Score

Excellent

STIM trades at attractive valuation levels.

PE < 25
-2.37
PEG Ratio < 2
-0.02

Growth Score

Excellent

STIM delivers strong and consistent growth momentum.

Revenue Growth > 5%
99.17%
EPS Growth > 10%
57.25%

Financial Health Score

Moderate

STIM shows balanced financial health with some risks.

Debt/Equity < 1
1.82
Current Ratio > 1
1.67

Profitability Score

Weak

STIM struggles to sustain strong margins.

ROE > 15%
-164.68%
Net Margin ≥ 15%
-24.48%
Positive Free Cash Flow
No

Key Financial Metrics

Is STIM Expensive or Cheap?

P/E Ratio

STIM trades at -2.37 times earnings. This suggests potential undervaluation.

-2.37

PEG Ratio

When adjusting for growth, STIM's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values Neuronetics, Inc. at 6.64 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.64

EV/EBITDA

Enterprise value stands at -2.95 times EBITDA. This is generally considered low.

-2.95

How Well Does STIM Make Money?

Net Profit Margin

For every $100 in sales, Neuronetics, Inc. keeps $-24.48 as profit after all expenses.

-24.48%

Operating Margin

Core operations generate -19.40 in profit for every $100 in revenue, before interest and taxes.

-19.40%

ROE

Management delivers $-1.65 in profit for every $100 of shareholder equity.

-1.65%

ROA

Neuronetics, Inc. generates $-29.59 in profit for every $100 in assets, demonstrating efficient asset deployment.

-29.59%

Following the Money - Real Cash Generation

Operating Cash Flow

Neuronetics, Inc. generates limited operating cash flow of $-12.80M, signaling weaker underlying cash strength.

$-12.80M

Free Cash Flow

Neuronetics, Inc. generates weak or negative free cash flow of $-13.58M, restricting financial flexibility.

$-13.58M

FCF Per Share

Each share generates $-0.20 in free cash annually.

$-0.20

FCF Yield

STIM converts -15.07% of its market value into free cash.

-15.07%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.37

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.64

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.58

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.82

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.67

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.65

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.30

vs 25 benchmark

How STIM Stacks Against Its Sector Peers

MetricSTIM ValueSector AveragePerformance
P/E Ratio-2.3729.20 Better (Cheaper)
ROE-164.68%729.00% Weak
Net Margin-24.48%-52856.00% (disorted) Weak
Debt/Equity1.820.49 Weak (High Leverage)
Current Ratio1.674.43 Neutral
ROA-29.59%-20711.00% (disorted) Weak

STIM outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Neuronetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-13.50%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

59.43%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

79.50%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ